Phase 1
Completed N=10
Opioid and Cannabinoid Interactions
Marijuana Usage · Opioid Use Disorder
Source: ClinicalTrials.gov NCT03705559 ↗
Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcomePrimary: Change in Subject-Rated Outcome - VAS Drug Liking — 3; 53.33; 58.89; 38.78 score on a scale
Summary
This study will examine the effects of doses of marijuana/placebo and doses of opioid/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) to determine the interaction effects of these compounds.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Subject-Rated Outcome - VAS Drug Liking |
3; 53.33; 58.89; 38.78; 35.22; 48.67 | — |
| SECONDARY Change in Oxygen Saturation |
96.56; 96.44; 96.44; 96.44; 96.11; 96.22 | — |
| SECONDARY Change in Respiration Rate |
11.89; 11.44; 12.44; 11.22; 10.22; 10.89 | — |
| SECONDARY Change in Systolic Blood Pressure |
133.56; 134.06; 140.56; 136.33; 134.33; 138.11 | — |
| SECONDARY Change in Diastolic Blood Pressure |
89.44; 97.18; 94.92; 94.08; 91.78; 91.83 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy adults ages 18-50
- Current non-medical use of opioids and marijuana
Exclusion Criteria
- Physical dependence on opioids, alcohol benzodiazepines/sedative/hypnotics
- Seeking treatment for drug use
- Significant medical problems
Data sourced from ClinicalTrials.gov (NCT03705559). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.